Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    22785351 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
Condition: Neoplasms, Breast
Interventions: Drug: Lapatinib;   Biological: Trastuzumab;   Drug: Paclitaxel

Study has passed its completion date and status has not been verified in more than two years.